AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second-half growth forecast boosted its shares.Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Union lawsuit.AstraZeneca, which has said it will not make a profit from the shot during the pandemic, was reporting financial details of distribution and sales of the vaccine it developed with Oxford University for the first time.It said the revenue included delivery of about 68.